Pathway to global elimination of hepatitis B: HBV cure is just the first step.
Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, de Santis T, Adda D, El-Sayed M, Feld JJ, Gane E, Lacombe K, Lesi O, Mohamed R, Silva M, Tu T, Revill P, Hellard ME
Hepatitis B
The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
Xiao Y, Hellard ME, Thompson AJ, Seaman C, Howell J, Scott N
Hepatitis B
Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis.
Seaman CP, Kahn AL, Kristensen D, Steinglass R, Spasenoska D, Scott N, Morgan C
Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.
Seaman CP, Mvundura M, Frivold C, Morgan C, Jarrahian C, Howell J, Hellard M, Scott N
Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP, Morgan C, Howell J, Xiao Y, Spearman CW, Sonderup M, Lesi O, Andersson MI, Hellard ME, Scott N
Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model.
Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME
- 1
- 2